His primary areas of investigation include Cancer research, Drug resistance, Cancer, Tubulin and Pharmacology. His Cancer research research incorporates themes from Cell culture, ATP-binding cassette transporter, Phosphorylation, Tumor suppressor gene and Programmed cell death. His study in the fields of Multiple drug resistance under the domain of Drug resistance overlaps with other disciplines such as Epigenesis.
His Cancer study combines topics from a wide range of disciplines, such as Microrna profiling, Gene expression profiling, Malignancy and microRNA. The study incorporates disciplines such as Molecular biology, Epothilones and Paclitaxel in addition to Tubulin. His study in Pharmacology is interdisciplinary in nature, drawing from both P-glycoprotein and Chemotherapy.
His scientific interests lie mostly in Internal medicine, Oncology, Cancer research, Cancer and Pharmacology. Tito Fojo interconnects Endocrinology, Surgery and Pathology in the investigation of issues within Internal medicine. His Cancer research research is multidisciplinary, relying on both Cell culture, Multiple drug resistance, Drug resistance, Cancer cell and Microtubule.
His research on Drug resistance frequently links to adjacent areas such as Drug. He has researched Cancer in several fields, including Gene and Immunology. His Pharmacology research incorporates elements of Vinblastine, Paclitaxel, Chemotherapy and P-glycoprotein.
His primary areas of study are Internal medicine, Oncology, Cancer, Cancer research and Hazard ratio. His Internal medicine study incorporates themes from Paraganglioma and Pathology. The various areas that Tito Fojo examines in his Oncology study include Regimen, Breast cancer, Prostate cancer and Cisplatin.
His research in Cancer intersects with topics in Clinical trial, Gene, Adrenocortical carcinoma and Intensive care medicine. The Cancer research study combines topics in areas such as STK11, Loss function, Drug resistance and Carcinogenesis. His work on Multiple drug resistance as part of general Drug resistance study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Tito Fojo mostly deals with Internal medicine, Oncology, Cancer, Intensive care medicine and MEDLINE. Head and neck squamous-cell carcinoma, Neutropenia, Chemoradiotherapy, Proportional hazards model and Chemotherapy are among the areas of Internal medicine where Tito Fojo concentrates his study. In his study, Discontinuation is inextricably linked to Clinical trial, which falls within the broad field of Oncology.
His Intensive care medicine study frequently draws connections between related disciplines such as Pharmacology. His Pharmacology study often links to related topics such as Bevacizumab. His MEDLINE study which covers Precision medicine that intersects with Cancer genome, Medical prescription, Clinical significance, Cancer Medicine and Targeted therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Multidrug resistance in cancer: role of ATP–dependent transporters
Michael M. Gottesman;Tito Fojo;Susan E. Bates.
Nature Reviews Cancer (2002)
Tumour stem cells and drug resistance
Michael Dean;Tito Fojo;Susan Bates.
Nature Reviews Cancer (2005)
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
John N. Weinstein;Timothy G. Myers;Patrick M. O'Connor;Stephen H. Friend.
The Role of ABC Transporters in Clinical Practice
Gregory D. Leonard;Tito Fojo;Susan E. Bates.
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
Keisuke Miyake;Lyn Mickley;Thomas Litman;Zhirong Zhan.
Cancer Research (1999)
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization
Paraskevi Giannakakou;Dan L. Sackett;Yoon-Koo Kang;Zhirong Zhan.
Journal of Biological Chemistry (1997)
Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute's Anticancer Drug Screen Panel
Olivier Rixe;Waldo Ortuzar;Manuel Alvarez;Ricardo Parker.
Biochemical Pharmacology (1996)
Delivering affordable cancer care in high-income countries
Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg.
Lancet Oncology (2011)
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht;Massimo Terzolo;Bruno Allolio;Eric Baudin.
The New England Journal of Medicine (2012)
A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
Paraskevi Giannakakou;Rick Gussio;Eva Nogales;Kenneth H. Downing.
Proceedings of the National Academy of Sciences of the United States of America (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: